Mass General Brigham’s Jounce Therapeutics JNCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-20,957
Closed -$142K – 5
2022
Q1
$142K Buy
+20,957
New +$149K 0.06% 5
2021
Q3
– Sell
-19,291
Closed -$131K – 12
2021
Q2
$131K Buy
+19,291
New +$160K 0.03% 9

Other funds holding JNCE

Mass General Brigham's JNCE Position: Q2 2022 in Review

Mass General Brigham sold out of Jounce Therapeutics (JNCE) in Q2 2022, closing a stake of 20,957 shares — an estimated $142K sold.

Mass General Brigham first reported a position in JNCE in Q2 2021 and held it in 2 quarters. The position peaked at $142K in Q1 2022. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.

  • Mass General Brigham reported no remaining Jounce Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Mass General Brigham sold 20,957 Jounce Therapeutics shares in Q2 2022, an estimated $142K.
  • Mass General Brigham first reported a position in Jounce Therapeutics in Q2 2021 and held it in 2 quarters.
  • Mass General Brigham's Jounce Therapeutics position peaked at $142K in Q1 2022.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics as of Q2 2022.

Based on Mass General Brigham's 13F filing for Q2 2022, filed 27 Jul 2022.